Orelabrutinib with R-CHOP for newly diagnosed lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial tests whether adding orelabrutinib to standard chemotherapy (R-CHOP) can improve treatment for people with newly diagnosed double-expressing diffuse large B-cell lymphoma. It’s intended for adults who are well enough to receive treatment and whose lymphoma is in the body (not in the brain/spinal fluid).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with double-expressing diffuse large B-cell lymphoma
- You are age 18 to 70
- You are able to do daily activities with limited assistance (ECOG 0–2)
- Your lymphoma is stage II to IV (not only stage I)
- You have no lymphoma in the central nervous system (brain/spinal fluid)
- You can receive treatment safely: no uncontrolled serious heart/stroke problems, active infections like hepatitis B/C or HIV, or plans for a transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (orelabrutinib and rituximab) compared to the standard R-CVP chemotherapy for people with newly diagnosed marginal zone lymphoma. The goal is to see which approach works better and has fewer side effects.
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
This trial tests an oral targeted therapy (orelabrutinib) for people with early-stage marginal zone lymphoma who have not yet had treatment. The goal is to see if this medication can control the cancer with fewer side effects than standard treatments.
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
This trial tests a new combination of drugs for people newly diagnosed with an aggressive type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The combo includes orelabrutinib plus standard chemo-immunotherapy, and may help improve outcomes for those at intermediate or high risk.
Hear when a new The First Affiliated Hospital of Nanchang University trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.